Navigation Links
Bone Biologics Announces Another Round of Equity and Debt Investment by Musculoskeletal Transplant Foundation and the Addition of Board Member, Mark Spilker
Date:3/10/2010

THOUSAND OAKS, Calif., March 10 /PRNewswire/ -- Bone Biologics, Inc. announced today it had received another round of investment for preferred shares from the Musculoskeletal Transplant Foundation (MTF). MTF now owns 51% of Bone Biologics. As part of the financing, MTF also provided a line of credit to fund continuing operations.  This financial support continues the investments by MTF that have allowed Bone Biologics, Inc. to progress from research through development of the NELL-1 protein sequence UCB-1 to the current culmination of:

  • Therapeutic validation in non-human primate trials
  • Economic manufacturing of cGMP grade product
  • Patent protected portfolio of claims

The platform technology will be subject to the FDA review and approval process, including clinical trials.  It is not currently approved for use in humans.

Additionally, Mark Spilker, PhD, MTF's Vice President, Research & Development, has been elected to the Bone Biologics, Inc. Board of Directors. Over his career, Dr. Spilker has been responsible for leading development and program management teams in the areas of tissue-engineered biologics, electro-mechanical devices, and electronics. He has launched many new products and served as a company resource for best practices in product development and design controls.

He holds a Bachelor of Science degree in Mechanical Engineering from the University of Utah. He also attended Massachusetts Institute of Technology where he earned both a Master of Science and a Doctor of Philosophy in Mechanical Engineering.

Bruce A. Hazuka, President and CEO of Bone Biologics, Inc. said, "We very much appreciate the continued support of MTF and believe that the experience of Mark Spilker will add expertise to our research, development, and ultimate commercialization of our unique UCB-1 protein."

Musculoskeletal Transplant Foundation

MTF is a non-profit service organization dedicated to providing quality tissue through a commitment to excellence in education, research, recovery and care for recipients, donors and their families. In 2009, MTF distributed over 415,000 tissue grafts.

Bone Biologics, Inc.

Bone Biologics is a convergence biotechnology company focused in the orthobiologics space.  The company was founded in 2004 by the research scientists who had identified and validated the product in the lab over the previous ten years.  The acquisition of an exclusive worldwide license from UCLA and the both the financing and strategic support from MTF was the genesis of the development of this recombinant protein.

For information: Bruce A. Hazuka/Bone Biologics/818-324-2742

SOURCE Bone Biologics, Inc.

Back to top
'/>"/>
SOURCE Bone Biologics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Shire Provides Update on Biologics License Application (BLA) Filing for REPLAGAL(R) (agalsidase alfa) With the U.S. Food and Drug Administration (FDA)
2. In 2012, Stelara and Briakinumab Will Capture 22 Percent of the Biologics Share in the Moderate to Severe Psoriasis Drug Market
3. Dendreon Completes Submission of Biologics License Application for PROVENGE
4. ImaginAb, Inc. and BZL Biologics, LLC Conclude Licensing Agreement for Imaging Rights to huJ591/Prostate-Specific Membrane Antigen (PSMA)
5. Crescendo Biologics Raises GBP4.5 million in Seed-Funding Led by Sofinnova Partners
6. Avaxia Biologics Awarded Phase I SBIR Grant to Develop Antibody Therapeutic for Oral Mucositis
7. Cardium Announces New Orthobiologics Product Initiative Extending Gene Activated Matrix Technology to Deliver Bone Growth Factors
8. Mylan Announces Strategic Collaboration with Biocon to Enter the Global Generic Biologics Market
9. ViroPharma Receives Complete Response Letter for Cinryze(TM) Supplemental Biologics License Application for Acute Treatment of Hereditary Angioedema
10. BioSpecifics Technologies Corp. Announces FDA Acceptance of Biologics License Application With Priority Review for XIAFLEX(TM) for the Treatment of Dupuytrens Disease
11. LaVoie Group Adds Bio-Surgery Company, Pegasus Biologics, to Its Life Sciences Agency Roster
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2017)... ... September 19, 2017 , ... A best-selling author ... tech companies. “Grit” author Angela Duckworth and her team at Character Lab have ... Cooley, an international law firm with decades of experience supporting high-growth companies in ...
(Date:9/19/2017)... ... 19, 2017 , ... The new and improved Oakton® pocket testers, from Cole-Parmer, ... upright with a new cap design that is versatile, functional and leakproof. They are ... to test water quality. , The Oakton pocket testers have many user-friendly and functional ...
(Date:9/19/2017)... , Sept. 19, 2017 ValGenesis Inc., the ... is pleased to announce the strategic partnership with VTI ... clients with validation services using the latest technology available ... will provide clients with efficient and cost-effective validation services ... partner for the ValGenesis VLMS system. ...
(Date:9/19/2017)... ... September 19, 2017 , ... Molecular Devices, ... with Cytena GmbH to launch the CloneSelect™ Single-Cell Printer™ in North America. ... single cells and provide visual documentation of monoclonality for use in cell line ...
Breaking Biology Technology:
(Date:4/13/2017)... PUNE, India , April 13, 2017 According ... Identity Proofing, Identity Authentication, Identity Analytics, Identity Administration, and Authorization), Service, Authentication ... by MarketsandMarkets™, the IAM Market is expected to grow from USD 14.30 ... Annual Growth Rate (CAGR) of 17.3%. ... ...
(Date:4/11/2017)... Research and Markets has announced the addition of the "Global ... ... at a CAGR of 30.37% during the period 2017-2021. ... based on an in-depth market analysis with inputs from industry experts. ... the coming years. The report also includes a discussion of the ...
(Date:4/11/2017)... , April 11, 2017 NXT-ID, Inc. ... technology company, announces the appointment of independent Directors Mr. ... to its Board of Directors, furthering the company,s corporate governance ... Gino ... we look forward to their guidance and benefiting from their ...
Breaking Biology News(10 mins):